Wanjia Group Holdings Limited (0401)
Market Closed
13 Aug, 08:00
HKEX HKEX Primary 0. 13
HKD +0.03
+23.8095%
82.35M Market Cap
- P/E Ratio
- Div Yield
420,000 Volume
- Eps
0.1 HKD
Previous Close Want to track 0401 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
0401 closed yesterday higher at 0.13 HKD, an increase of 23.8095% from Wednesday's close, completing a monthly increase of 4% or 0.01 HKD. Over the past 12 months, 0401 stock gained 28.7129%.
0401 is not paying dividends to its shareholders.
Wanjia Group Holdings Limited has completed 1 stock splits, with the recent split occurring on Jan 20, 2020.
The company's stock is traded on one exchange.
0401 Chart
Wanjia Group Holdings Limited (0401) FAQ
What is the stock price today?
The current price is 0.13 HKD.
On which exchange is it traded?
Wanjia Group Holdings Limited is listed on HKEX.
What is its stock symbol?
The ticker symbol is 0401.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 82.35M.
Has Wanjia Group Holdings Limited ever had a stock split?
Wanjia Group Holdings Limited had 1 splits and the recent split was on Jan 20, 2020.
Wanjia Group Holdings Limited Profile
| Consumer Staples Distribution & Retail Industry | Consumer Staples Sector | Mr. Jia Jun Wang CEO | HKEX Exchange | KYG9431A1186 ISIN |
| Hong Kong Country | 177 Employees | - Last Dividend | 20 Jan 2020 Last Split | - IPO Date |
Overview
Wanjia Group Holdings Limited is an investment holding company that has carved a niche in the pharmaceutical industry by focusing on wholesale and distribution within Mainland China and Hong Kong. Established in 2004 and based in Kowloon, Hong Kong, the company leverages its strategic geographic location to serve a broad segment of the healthcare industry. In addition to its core operations in pharmaceutical distribution, Wanjia Group Holdings Limited has diversified its business by offering hemodialysis treatment and consultancy services, showcasing its commitment to addressing a wide range of healthcare needs.
Products and Services
- Pharmaceutical Wholesale and Distribution: This encompasses a core aspect of Wanjia's business model, targeting hospitals, healthcare institutions, and pharmaceutical retail chains. Their distribution network is extensive, catering to the requirements of independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics primarily located in Fujian province. This strategically positions Wanjia as a significant player in the pharmaceutical distribution sector.
- Hemodialysis Treatment: Wanjia Group has expanded into providing hemodialysis treatment services. This pivotal move not only diversifies their service portfolio but also addresses the growing demand for quality renal care services. By offering such specialized treatment options, the company significantly contributes to improving the quality of life for patients with renal impairments, establishing itself as a comprehensive healthcare provider.
- Consultancy Services: Understanding the complex landscape of the healthcare industry, Wanjia also offers consultancy services. This strategic move capitalizes on their industry expertise and insights, providing invaluable guidance to healthcare entities. These services are aimed at improving operational efficiencies, regulatory compliance, and overall business performance for their clients, further solidifying Wanjia's stature as a trusted advisor in the healthcare sector.
Contact Information
Address: Tower 1
Phone: 852 2366 3375
Website: https://www.wanjia-gp.com
